Table 1: Age presentation group analyses.
|
< 20 years N = 8 |
20 to < 30 N = 22 |
30 to < 40 N = 22 |
40 to < 50 N = 30 |
50 to < 60 N = 53 |
60 to < 70 N = 46 |
> 70 N = 29 |
Gender (p = 0.791) |
|
|
|
|
|
|
|
Female |
3 (37.5) |
12 (54.5) |
11 (50.0) |
11 (36.7) |
21 (39.6) |
23 (50.0) |
13 (44.8) |
Male |
5 (62.5) |
10 (45.5) |
11 (50.0) |
19 (63.3) |
32 (60.4) |
23 (50.0) |
16 (55.2) |
Ethnic (p = 0.046*) |
|
|
|
|
|
|
|
Chinese |
3 (37.5) |
7 (31.8) |
11 (50.0) |
15 (50.0) |
29 (54.7) |
28 (60.9) |
18 (62.1) |
Malay |
4 (50.0) |
13 (59.1) |
7 (31.8) |
4 (13.3) |
14 (26.4) |
12 (26.1) |
4 (13.8) |
Indian |
0 (0.0) |
0 (0.0) |
1 (4.5) |
6 (20.0) |
5 (9.4) |
1 (2.2) |
3 (10.3) |
Others |
1 (12.5) |
2 (9.1) |
3 (13.6) |
5 (16.7) |
5 (9.4) |
5 (10.9) |
4 (13.8 ) |
Site (p = 0.178) |
|
|
|
|
|
|
|
Nodal |
2 (25.0) |
11 (50.0 ) |
6 (27.3 ) |
14 (46.7) |
30 (56.6) |
23 (50.0) |
10 (34.5) |
Extranodal |
6 (75.0) |
11 (50.0) |
16 (72.7) |
16 (53.3) |
23 (43.4) |
23 (50.0) |
19 (65.5) |
Lymphoma Subtype |
|
|
|
|
|
|
|
DLBCL, NOS |
2 (25.0) |
6 (27.2) |
12 (54.5) |
9 (30.0) |
30 (56.6) |
28 (60.9) |
20 (69.0) |
Plasmablastic |
1 (12.5) |
0 (0.0) |
0 (0.0) |
1 (3.3) |
1 (1.9) |
0 (0.0) |
1 (3.4) |
FL |
0 (0.0) |
0 (0.0) |
1 (4.5) |
8 (26.7) |
8 (15.1) |
4 (8.7) |
0 (0.0) |
MZL |
0 (0.0) |
0 (0.0) |
3 (13.6) |
2 (6.7) |
2 (3.8) |
6 (13.0) |
3 (10.3) |
MCL |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
2 (3.8) |
2 (4.3) |
2 (6.9) |
BL |
3 (37.5) |
0 (0.0) |
2 (9.1) |
1 (3.3) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
SLL |
0 (0.0) |
0 (0.0) |
0 (0.0) |
1 (3.3) |
1 (1.9) |
1 (2.2) |
0 (0.0) |
Lymphoblastic Lymphoma |
0 (0.0) |
0 (0.0) |
1 (4.5) |
0 (0.0) |
1 (1.9) |
0 (0.0) |
1 (3.4) |
B-cell NHL (No category) |
0 (0.0) |
1 (4.5) |
1 (4.5) |
2 (6.7) |
2 (3.8) |
1 (2.2) |
2 (6.9) |
T-cell NHL |
0 (0.0) |
0 (0.0) |
1 (4.5) |
3 (10.0) |
4 (7.5) |
2 (4.3) |
0 (0.0) |
HL |
2 (25.0) |
15 (68.2) |
1 (4.5) |
3 (10.0) |
2 (3.8) |
2 (4.3) |
0 (0.0) |